ClinicalTrials.Veeva

Menu

A Post-Market Clinical Follow-up Investigation to Verify Performance and Safety of Viiral®Nasal Spray in Subjects With Dry Nose Symptoms

V

Viiral Nordic

Status

Completed

Conditions

Rhinitis Sicca

Treatments

Device: Isotonic Saline Nasal Spray
Device: Sialic acid nasal spray

Study type

Interventional

Funder types

Industry

Identifiers

NCT05264350
Vii-001

Details and patient eligibility

About

A chronic irritation of the nasal mucosa can be painful and unpleasant for the individual. Dry nasal mucosa with scabs is a common problem but not everyone seeks care. The causes can be several such as staying for long periods in dry and dusty air, hot rooms or hot environments, tobacco smoke, side effects of drugs and mechanical irritation (nasal congestion). The nasal spray contains salic acid (neuraminic acid). This substance is found naturally in humans in the nasal mucosa which keeps it moist. Salic acid is also found, for example, in breast milk and is also found in food production. Previous studies have shown that treatment with salic acid is gentle, relieves symptoms and has a soothing and moisturising effect.

The purpose of the study is to evaluate whether the symptoms of dry nose can be improved with treatment with Viiral®Nasal spray and have a soothing and moisturising effect. The treatment also aims to prevent colds caused by viruses.

As a control product in the study, a nasal spray with isotonic saline solution will be used. In this study, a total of 78 women and men who have been diagnosed with dry nose / rhinitis sicca will be included in the study. After the participants have given their consent to participate in the study, treatment with the study product or control product will begin. The treatment is started by the study participants themselves at home. Two thirds will be treated with the study product and one third will be treated with a control product. Clinic visits will be performed at three occasions after the screening/baseline visit, at day 14, day 28 and on day 56.

Enrollment

84 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Signed Informed Consent Form.
  • Adult males and females ≥ 18 years old.
  • Score of at least 10 as indication for application of moistening nasal sprays per investigator judgement, confirmed with a total Rhinitis Sicca Symptom Score (sensation of dry nose, nasal obstruction, crusting, itching/sneezing attacks, pain in the nose, runny nose, thick nasal discharge, dry throat, impairment of smell and impairment of sleep) using a 5-point severity scale (0=none, 1=mild, 2=moderate, 3=strong, and 4 = very strong.
  • Able to use the device independently.

Exclusion criteria

  • Antiallergy drugs and rhinitis medication, including rescue medication for symptom relief and anti-hyperactivity last week.
  • Pregnancy or lactation at time of investigation participation.
  • Physical or mental impairment affecting subjects' ability to use the device, per investigator judgement.
  • Person not suitable for the investigation according to the investigator judgement.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

84 participants in 2 patient groups

Viiral® Nasal Spray group
Experimental group
Description:
The nasal spray to be administrated twice daily for 8 weeks.
Treatment:
Device: Sialic acid nasal spray
Isotonic Saline Nasal Spray
Active Comparator group
Description:
The nasal spray to be administrated twice daily for 8 weeks.
Treatment:
Device: Isotonic Saline Nasal Spray

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems